Baltimore’s emocha Mobile Health won a Small Business Innovation Research award from the National Institutes of Health to study its medication adherence platform for patients with tuberculosis, the company announced.
The award gives emocha $1 million for a multi-state study conducted by researchers at Johns Hopkins University’s School of Medicine.
“We value conducting rigorous scientific research to measure the impact of our technology and are honored to be able to do so through this NIH mechanism,” Sebastian Seiguer, the company’s CEO, said in a statement.
The company’s platform allows patients and their health care providers to ensure adherence to medicines that typically require in-person observation. Using emocha’s app, patients can record themselves taking their medicine, saving them from having to meet up with a health care provider.
That can be particularly helpful in cases such as tuberculosis, a disease with treatments that require direct observation, because the disease disproportionately affects people who can be difficult to reach with standard care, the company said.
The new study will build on previous work conducted by Hopkins researchers in Maryland. That study found that through the emocha platform, patients had 94 percent medication adherence, potentially saving public health programs nearly $1,400 per patient.
In addiction to tuberculosis, emocha’s platform has been tested for other infectious and chronic conditions, including medication-assisted treatment for opioid misuse.